TickerFacts.

OS Therapies Inc (OSTX): EBITDA

Operating income plus depreciation and amortization for the same annual period and currency, computed by TickerFacts from the filed figures. Not the company's adjusted EBITDA; a year without both inputs is left out.

-$28.34M
Year ended 2025-12-31
-$37.11M
Trailing 12 months to 2026-06-30
2024-12-31: -$6.81M2025-12-31: -$28.34M-$28.34M
2024-12-31 EBITDA (USD) 2025-12-31
Period endedEBITDAChange YoYSource filing
2025-12-31-$28.34Mn/m2026-03-31, From 2025-01-01
2024-12-31-$6.81Mn/a2026-03-31, From 2024-01-01

EBITDA at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedEBITDAChange YoY
OS Therapies Inc (OSTX)2025-12-31-$28.34Mn/m
Serina Therapeutics, Inc. (SER)2025-12-31-$23.95Mn/m
CV Sciences, Inc. (CVSI)2025-12-31-$278.0Kn/m
Cannapharmarx, Inc. (CPMD)2024-12-31-$3.63Mn/m
Vyome Holdings, Inc (HIND)2025-12-31-$10.44Mn/m
Matinas BioPharma Holdings, Inc. (MTNB)2025-12-31-$6.93Mn/m
GeoVax Labs, Inc. (GOVX)2025-12-31-$21.57Mn/m
Ernexa Therapeutics Inc. (ERNA)2025-12-31-$9.25Mn/m
Lunai Bioworks Inc. (LNAI)2025-06-30-$188.84Mn/m

Compare OSTX, SER, CVSI, CPMD side by side · Screen every company in Pharmaceutical Preparations ↗